These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7351119)

  • 1. Prevalence of high (3S)-3-hydroxyquinidine/quinidine ratios in serum, and clearance of quinidine in cardiac patients with age.
    Drayer DE; Hughes M; Lorenzo B; Reidenberg MM
    Clin Pharmacol Ther; 1980 Jan; 27(1):72-5. PubMed ID: 7351119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function.
    Drayer DE; Lowenthal DT; Restivo KM; Schwartz A; Cook CE; Reidenberg MM
    Clin Pharmacol Ther; 1978 Jul; 24(1):31-9. PubMed ID: 657716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high-pressure liquid chromatography.
    Drayer DE; Restivo K; Reidenberg MM
    J Lab Clin Med; 1977 Nov; 90(5):816-22. PubMed ID: 908870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.
    Wooding-Scott RA; Visco J; Slaughter RL
    Am Heart J; 1987 Feb; 113(2 Pt 1):302-6. PubMed ID: 3812182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid chromatography and fluorescence spectroscopy compared with a homogeneous enzyme immunoassay technique for determining quinidine in serum.
    Drayer DE; Lorenzo B; Reidenberg MM
    Clin Chem; 1981 Feb; 27(2):308-10. PubMed ID: 7006859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-pressure liquid chromatography method for serum quinidine and (3S)-3-hydroxyquinidine.
    Weidner N; Ladenson JH; Larson L; Kessler G; McDonald JM
    Clin Chim Acta; 1979 Jan; 91(1):7-13. PubMed ID: 761394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
    Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
    J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing.
    Russo J; Russo ME; Smith RA; Pershing LK
    J Clin Pharmacol; 1982; 22(5-6):264-70. PubMed ID: 7107973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of quinidine in the rabbit.
    Guentert TW; Huang JD; Oie S
    J Pharm Sci; 1982 Jul; 71(7):812-5. PubMed ID: 7120069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.
    Edwards DJ; Axelson JE; Visco JP; vanEvery S; Slaughter RL; Lalka D
    Br J Clin Pharmacol; 1987 Mar; 23(3):351-4. PubMed ID: 3567051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent kinetics of quinidine in the perfused rat liver preparation. Kinetics of formation of active metabolites.
    Yu VC; de Lamirande E; Horning MG; Pang KS
    Drug Metab Dispos; 1982; 10(6):568-72. PubMed ID: 6130901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinidine-digoxin interaction: time course and pharmacokinetics.
    Leahey EB; Bigger JT; Butler VP; Reiffel JA; O'Connell GC; Scaffidi LE; Rottman JN
    Am J Cardiol; 1981 Dec; 48(6):1141-6. PubMed ID: 7304462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.
    Vozeh S; Uematsu T; Guentert TW; Ha HR; Follath F
    Clin Pharmacol Ther; 1985 May; 37(5):575-81. PubMed ID: 3987181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
    Damkier P; Brøsen K
    Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fetal supraventricular tachycardia treated with high-dose quinidine: toxicity associated with marked elevation of the metabolite, 3(S)-3-hydroxyquinidine.
    Killeen AA; Bowers LD
    Obstet Gynecol; 1987 Sep; 70(3 Pt 2):445-9. PubMed ID: 3627599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic activity of two quinidine metabolites in experimental reperfusion arrhythmia: relative potency and pharmacodynamic interaction with the parent drug.
    Vozeh S; Oti-Amoako K; Uematsu T; Follath F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):297-301. PubMed ID: 3668860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and dynamics of quinidine-N-oxide in healthy subjects.
    Ha HR; Vozeh S; Uematsu T; Guentert TW; Follath F
    Clin Pharmacol Ther; 1987 Sep; 42(3):341-5. PubMed ID: 3621790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes.
    Thompson KA; Murray JJ; Blair IA; Woosley RL; Roden DM
    Clin Pharmacol Ther; 1988 Jun; 43(6):636-42. PubMed ID: 3378385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of quinidine metabolites to electrophysiologic responses in human subjects.
    Kavanagh KM; Wyse DG; Mitchell LB; Gilhooly T; Gillis AM; Duff HJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):352-8. PubMed ID: 2776394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical pharmacokinetics and pharmacodynamics of quinidine].
    Kholodov LE; Glezer MG; Makharadze RV
    Kardiologiia; 1983 Aug; 23(8):107-14. PubMed ID: 6353039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.